NFE2L2 and neoplasm: These findings suggest a possible therapeutic application of bardoxolone methyl which could selectively enhance the resilience of normal tissues to ionizing radiation via Nrf2 activation, without safeguarding tumor cells, making it a promising non-toxic drug which could be an adjunct in radiation oncology to minimize treatment-associated toxicity and improve clinical outcomes [77].